Physician profile
Scott D Lanoux
NPI 1922047406
$7,771.69
in general payments reported to CMS, 2019-2025
30 companies · $1,431 in 2025
The $1,431 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,437 · 2020: $142 · 2021: $1,056 · 2022: $795 · 2023: $1,671 · 2024: $1,240 · 2025: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,341.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,936.13 | 2019-2025 | Clareon, Argos, Rocklatan |
| Ivantis, INC | $715.12 | 2019-2021 | |
| Sight Sciences, INC. | $550.87 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| New World Medical,INC. | $378.73 | 2023-2025 | Via360, Clearpath, Streamline |
| Tarsus Pharmaceuticals, INC. | $297.15 | 2025 | Xdemvy |
| Glaukos Corporation | $296.34 | 2019-2025 | Photrexa Cross-Linking Kit, Idosetr |
| Sun Pharmaceutical Industries INC. | $251.30 | 2019-2023 | Cequa |
| Allergan, INC. | $245.03 | 2019-2022 | |
| Dompe US, INC. | $198.55 | 2023-2025 | Oxervate |
| Rxsight INC | $190.85 | 2022-2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Apellis Pharmaceuticals, INC. | $190.18 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $161.47 | 2021-2025 | Tecnis Simplicity |
| Horizon Therapeutics Plc | $141.62 | 2021-2022 | |
| Genentech USA, INC. | $132.51 | 2022 | |
| Abbvie INC. | $132.11 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $125.00 | 2019 | |
| Mallinckrodt Hospital Products INC. | $124.99 | 2023 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $114.34 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $110.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $89.60 | 2019 | |
| Astellas Pharma US INC | $86.46 | 2023 | Izervay |
| Carl Zeiss Meditec, INC. | $75.52 | 2019 | |
| Oyster Point Pharma, INC. | $63.33 | 2023-2024 | Tyrvaya |
| Biotissue Holdings INC. | $47.68 | 2023-2025 | |
| Amgen INC. | $32.21 | 2025 | Tepezza |
| Harrow Eye, LLC | $22.32 | 2024 | Vevye |
| Aerie Pharmaceuticals, INC. | $16.16 | 2020 | |
| Ocular Therapeutix, INC. | $16.13 | 2022 | |
| Rayner Intraocular Lenses Limited | $15.02 | 2022 | |
| Bausch & Lomb Americas INC. | $14.54 | 2025 | Xiidra, Miebo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Lanoux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.